Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Table 3 Toxicity according to performance status and treatment

Toxicity	ECOG 2 group			ECOG 0–1 group			p^b
Toxicity	EP arm (n = 31)	PC arm (n = 40)	p^a	EP arm (n = 64)	PC arm (n = 56)	p^a	p^b
Hematological			0.663			0.725	0.854
Grade 3/4	10 (32.3%)	11 (27.5%)		19 (29.7%)	15 (26.8%)
Grade 1/2	21 (67.7%)	29 (72.5%)		45 (70.3%)	41 (73.2%)
Esophagitis			0.078			0.017	0.230
Grade 3	8 (25.8%)	4 (10.0%)		11 (17.2%)	2 (3.6%)
< Grade 3	23 (74.2%)	36 (90.0%)		53 (82.8%)	54 (96.4%)
Radiation pneumonitis			0.014			0.066	0.428
≥ Grade 3	0 (0.0%)	7 (17.5%)		7 (10.9%)	1 (1.8%)
< Grade 3	31 (100.0%)	33 (82.5%)		57 (89.1%)	55 (98.2%)
Gastrointestinal toxicity			0.327			0.285	0.950
≥ Grade 3	3 (9.7%)	8 (20.0%)		8 (12.5%)	11 (19.6%)
< Grade 3	28 (90.3%)	32 (80.0%)		56 (87.5%)	45 (80.4%)
Dermatological toxicity						0.598	0.296
≥ Grade 3	0 (0.0%)	0 (0.0%)		1 (1.6%)	2 (3.6%)
< Grade 3	31 (100.0%)	40 (100.0%)		63 (98.4%)	54 (96.4%)

Abbreviations: EP etoposide/cisplatin, PC paclitaxel/carboplatin, ECOG Eastern Cooperative Oncology Group
^ap value for testing the null hypothesis of no difference between patients receiving EP and PC chemotherapy
^bp value for testing the null hypothesis of no difference between ECOG 2 group and ECOG 0–1 group

ISSN: 1471-2407